Merck & Co., Inc. Depreciation
Merck & Co., Inc. (MRK) reported Depreciation of $1.18 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-07
- Merck & Co., Inc. depreciation for the quarter ending 2026-06-30 was $599.00M, a 15.64% increase year-over-year.
- Merck & Co., Inc. depreciation for the quarter ending 2026-03-31 was $581.00M, a 15.74% increase year-over-year.
- Merck & Co., Inc. depreciation for the quarter ending 2025-12-31 was $1.49B, a 186.02% increase year-over-year.
- Merck & Co., Inc. depreciation for the quarter ending 2025-09-30 was $532.00M, a 3.80% decline year-over-year.
- Merck & Co., Inc. depreciation for fiscal 2025 was $3.04B, a 44.72% increase from fiscal 2024.
- Merck & Co., Inc. depreciation for fiscal 2024 was $2.10B, a 15.10% increase from fiscal 2023.
- Merck & Co., Inc. depreciation for fiscal 2023 was $1.83B, a 0.22% increase from fiscal 2022.
- Merck & Co., Inc. depreciation for fiscal 2022 was $1.82B, a 15.59% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $599.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.18B 10-Q · filed 2026-08-07 | $2.67B derived: sum of 3 quarters · filed 2026-08-07 | $3.21B derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $581.00M 10-Q · filed 2026-05-04 | $2.07B derived: sum of 2 quarters · filed 2026-05-04 | $2.61B derived: sum of 3 quarters · filed 2026-05-04 | $3.12B derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | $1.49B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.02B derived: sum of 2 quarters · filed 2026-02-24 | $2.54B derived: sum of 3 quarters · filed 2026-08-07 | $3.04B 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $532.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.05B derived: sum of 2 quarters · filed 2026-08-07 | $1.55B 10-Q · filed 2025-11-05 | $2.07B derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $518.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.02B 10-Q · filed 2026-08-07 | $1.54B derived: sum of 3 quarters · filed 2026-08-07 | $2.10B derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $502.00M 10-Q · filed 2026-05-04 | $1.02B derived: sum of 2 quarters · filed 2026-05-04 | $1.58B derived: sum of 3 quarters · filed 2026-05-04 | $2.10B derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $522.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.07B derived: sum of 2 quarters · filed 2026-02-24 | $1.59B derived: sum of 3 quarters · filed 2026-02-24 | $2.10B 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $553.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.07B derived: sum of 2 quarters · filed 2025-11-05 | $1.58B 10-Q · filed 2025-11-05 | $2.08B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $518.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.03B 10-Q · filed 2025-08-05 | $1.53B derived: sum of 3 quarters · filed 2026-02-24 | $1.98B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $511.00M 10-Q · filed 2025-05-02 | $1.01B derived: sum of 2 quarters · filed 2026-02-24 | $1.47B derived: sum of 3 quarters · filed 2026-02-24 | $1.89B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $502.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $954.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.38B derived: sum of 3 quarters · filed 2026-02-24 | $1.83B 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $452.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $878.00M derived: sum of 2 quarters · filed 2024-11-06 | $1.33B 10-Q · filed 2024-11-06 | $1.76B derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2023-06-30 | $426.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $874.00M 10-Q · filed 2024-08-05 | $1.30B derived: sum of 3 quarters · filed 2025-02-25 | $1.80B derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2023-03-31 | $448.00M 10-Q · filed 2024-05-03 | $878.00M derived: sum of 2 quarters · filed 2025-02-25 | $1.38B derived: sum of 3 quarters · filed 2025-02-25 | $1.85B derived: sum of 4 quarters · filed 2025-02-25 | ||
| 2022-12-31 | $430.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $929.00M derived: sum of 2 quarters · filed 2025-02-25 | $1.40B derived: sum of 3 quarters · filed 2025-02-25 | $1.82B 10-K · filed 2025-02-25 | ||
| 2022-09-30 | $499.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $973.00M derived: sum of 2 quarters · filed 2023-11-03 | $1.39B 10-Q · filed 2023-11-03 | $1.82B derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-06-30 | $474.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $895.00M 10-Q · filed 2023-08-07 | $1.32B derived: sum of 3 quarters · filed 2024-02-26 | $1.72B derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2022-03-31 | $421.00M 10-Q · filed 2023-05-05 | $851.00M derived: sum of 2 quarters · filed 2024-02-26 | $1.25B derived: sum of 3 quarters · filed 2024-02-26 | $1.62B derived: sum of 4 quarters · filed 2024-02-26 | ||
| 2021-12-31 | $430.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $829.00M derived: sum of 2 quarters · filed 2024-02-26 | $1.20B derived: sum of 3 quarters · filed 2024-02-26 | $1.58B 10-K · filed 2024-02-26 | ||
| 2021-09-30 | $399.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $770.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.15B 10-Q · filed 2022-11-03 | $1.61B derived: sum of 4 quarters · filed 2023-02-24 | ||
| 2021-06-30 | $371.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $749.00M 10-Q · filed 2022-08-05 | $1.21B derived: sum of 3 quarters · filed 2023-02-24 | $1.61B derived: sum of 4 quarters · filed 2023-02-24 | ||
| 2021-03-31 | $378.00M 10-Q · filed 2022-05-05 | $396.00M 10-Q · filed 2021-05-05 | $837.00M derived: sum of 2 quarters · filed 2023-02-24 | $1.24B derived: sum of 3 quarters · filed 2023-02-24 | $1.64B derived: sum of 4 quarters · filed 2023-02-24 | |
| 2020-12-31 | $459.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $861.00M derived: sum of 2 quarters · filed 2023-02-24 | $1.26B derived: sum of 3 quarters · filed 2023-02-24 | $1.67B 10-K · filed 2023-02-24 | $1.73B 10-K · filed 2021-02-25 | |
| 2020-09-30 | $402.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $799.00M derived: sum of 2 quarters · filed 2021-11-05 | $1.21B 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | $397.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $808.00M 10-Q · filed 2021-08-09 | ||||
| 2020-03-31 | $411.00M 10-Q · filed 2021-05-05 | |||||
| 2019-12-31 | $1.61B 10-K · filed 2022-02-25 | $1.70B 10-K · filed 2020-02-26 | ||||
| 2018-12-31 | $1.42B 10-K · filed 2021-02-25 | $1.40B 10-K · filed 2019-02-27 | ||||
| 2017-12-31 | $1.50B 10-K · filed 2020-02-26 | |||||
| 2016-12-31 | $1.60B 10-K · filed 2019-02-27 | |||||
| 2015-12-31 | $1.60B 10-K · filed 2018-02-27 | |||||
| 2014-12-31 | $2.50B 10-K · filed 2017-02-28 | |||||
| 2013-12-31 | $2.20B 10-K · filed 2016-02-26 | |||||
| 2012-12-31 | $2.00B 10-K · filed 2015-02-27 | |||||
| 2011-12-31 | $2.40B 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |